Select Page
Home » Expert Content » Dose Form Design » Lipid-Based Delivery of Peptide Therapeutics

Lipid-Based Delivery of Peptide Therapeutics

Summary: According to recently published data, the market for peptide drugs has grown significantly and sales for insulin alone reached $25 billion in 2013 (Source: IMS Health), with growth forecast to continue at a pace. Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has invested significantly in developing a broad range of complex oral drug delivery technologies, with OptiGel Bio™ technology being one of the most applicable for peptide drug delivery.

Download the File